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A B S T R A C T
This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched donor between 2009
and 2015 enrolled in the European Society for Blood and Marrow Transplantation database. The median age was
57 years (range, 38 to 72); 75% had primary MF and 25% had secondary MF. JAK2 V617F was mutated in 61%.
Donors were HLA mismatched at 2 or more loci. Stem cells were sourced from bone marrow in 66% and peripheral
blood in 34%. The median CD34+ cell dose was 4.8£ 106/kg (range, 1.7 to 22.9; n = 43). Conditioning was predomi-
nantly myeloablative in 70% and reduced intensity in the remainder. Regimens were heterogeneous with thio-
tepa, busulfan, fludarabine, and post-transplant cyclophosphamide used in 59%. The incidence of neutrophil
engraftment by 28 days was 82% (range, 70% to 93%), at a median of 21 days (range, 19 to 23). At 2 years the cumu-
lative incidence of primary graft failure was 9% (95% CI 1% to 16%) and secondary graft failure was 13% (95% CI 4%
to 22%). The cumulative incidence of acute graft-versus-host disease (GVHD) grades II to IV and III to IV was 28%
(95% CI 16% to 40%) and 9% (95% CI 2% to 17%) at 100 days. The cumulative incidence of chronic GVHD at 1 year
was 45% (95% CI 32% to 58%), but the cumulative incidence of death without chronic GVHD by 1 year was 20%
(95% CI 10% to 31%). With a median follow-up of 32 months, the 1- and 2-year overall survival was 61% (95% CI
48% to 74%) and 56% (95% CI 41% to 70%), respectively. The 1- and 2- year progression-free survival was 58% (95%
CI 45% to 71%) and 43% (95% CI 28% to 58%), respectively, with a 2-year cumulative incidence of relapse of 19%
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(95% CI 7% to 31%). The 2-year nonrelapse mortality was 38% (95% CI 24% to 51%). This retrospective study of MF
allo-SCT using family mismatched donors demonstrated feasibility of the approach, timely neutrophil engraft-
ment in over 80% of cases, and acceptable overall and progression-free survival rates with relapse rates not dis-
similar to the unrelated donor setting. However, strategies to minimize the risk of graft failure and the relatively
high nonrelapse mortality need to be used, ideally in a multicenter prospective fashion.
© 2018 American Society for Blood and Marrow Transplantation.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(allo-SCT) for primary myelofibrosis (MF) and secondary
MF (postpolycythemia vera or postessential thrombocy-
themia MF) remains the only established curative therapy.
Current consensus European LeukemiaNetEuropean Soci-
ety for Blood and Marrow Transplantation (EBMT) guide-
lines recommend that all patients with intermediate-2 or
high-risk disease based on International Prognostic Scoring
System (IPSS), Dynamic (D)-IPSS, or DIPSS-plus score up to
age 70 years should be considered candidates for allo-SCT
[1]. Those with intermediate-1 risk disease up to age
65 years should also be considered candidates for allo-SCT
if they have either refractory or transfusion-dependent
anemia, a percentage of blasts > 2% in the peripheral blood,
or adverse cytogenetics [1].
The outcomes from such allo-SCT demonstrate survival
rates of 40% to 60% at 4 to 5 years, yet there remains a signifi-
cant transplant-related mortality of between 10% and 40%
[24]. Data from the Center for International Blood and
Marrow Transplant Research in the past decade indicate that
approximately 1440 patients with MF underwent either a
sibling or matched unrelated (MUD) donor transplant [5].
Within this period, although the numbers of haploidentical
donor transplants increased relative to other donor sources,
which remained stable in other disease types, this increase
was not seen for MF [5].
Few transplants using mismatched related donors
(MMRDs) in MF have been performed because of the risk of
nonengraftment, augmented graft-versus-host disease (GVHD)
rates, and historical exclusion of these patients from national
clinical trials, leading to a paucity of data. Current donor selec-
tion strategies in the absence of a matched related or unrelated
donor would consist of a mismatched unrelated donor
(MMUD) or double umbilical cord blood transplants. Histori-
cally, umbilical cord blood transplants were associated with a
higher graft failure rate that was abrogated by alterations to
the conditioning regimen but achieved 2-year overall survival
(OS) and disease-free survival rates of only 44% and 30%,
respectively [6].
Recently, a single center compared its contemporaneous sib-
ling (n = 11), unrelated (n = 6), and haploidentical (n = 20) trans-
plants for MF, predominantly using myeloablative conditioning
(MAC), demonstrating a 3-year transplant-related mortality of
16%, relapse rate of 16%, and actuarial OS of 70%, whereby sur-
vival of patients with an alternative donor was 69%—similar to
the 72% obtained withmatched sibling donors (MSDs) [7]. Given
the need for alternative donors we retrospectively studied the
outcomes of MMRD transplants recorded in the EBMT database
between 2009 and 2015.
METHODS
All patients provided informed consent for data registration, according to
the Declaration of Helsinki. This study was approved by the Chronic Malig-
nancies Working Party of the EBMT. Data were retrieved from the EBMT reg-
istry for MMRD transplants performed between 2009 and 2015. Because this
is a registry-based study, albeit very probable, it cannot be confirmed that all
consecutive patients from each center were submitted to the EBMT.
A MED-C questionnaire was sent to centers to complete missing data and
for diagnosis confirmation. Patients were included if the family donor was 2
Ag mismatch and at least haplotype (3/6) matched.
Neutrophil engraftment was defined as the time at which the absolute
neutrophil count was .5£ 109/L for 3 consecutive days and platelet engraft-
ment as a platelet count > 20£ 109/L for 7 consecutive days without transfu-
sion support. Primary graft failure was defined as failing to reach a neutrophil
count > .5£ 109/L in the first 28 days after SCT or documentation of autolo-
gous reconstitution by chimerism analysis in the absence of relapse [8]. Sec-
ondary graft failure was defined by the treating physician: Standard criteria
across Europe would be loss of a functioning graft demonstrated by cytopenia
in at least 2 lineages and loss of donor chimerism.
Complete remission was conventionally defined if all the following were
achieved: resolution of disease-related symptoms and signs including palpa-
ble hepatosplenomegaly, hemoglobin > 11 g/dL, platelets > 100£ 109/L, and
neutrophils > 1£ 109/L with normal bone marrow histology and fibrosis
grade no higher than 1. Relapse was defined as loss of complete remission.
For this study both complete remission and relapse were designated by the
treating physician.
Conditioning regimes were defined as MAC if they contained either total
body irradiation (TBI) with a dose > 6 Gy, oral busulfan dose > 8 mg/kg, or i.v.
busulfan> 6.4 mg/kg. Additional variables included remission status, stem cell
source, donor gender, donorrecipient gender match, and recipient age.
Pretransplant patient characteristics were expressed as the median and
range for continuous variables and frequencies and proportions for categori-
cal variables. Primary endpoints were OS, progression-free survival (PFS),
cumulative incidence of relapse/progression (CIR), and nonrelapse mortality
(NRM), evaluated at 24 months after transplant. Median follow-up was deter-
mined using the reverse Kaplan-Meier method. The cumulative incidences of
grades II to IV and III to IV acute GVHD (aGVHD) and limited/extensive
chronic GVHD (cGVHD) were also estimated at 100 days and 12 and 24
months, respectively. The cumulative incidences of neutrophil and platelet
engraftment were estimated at 28 days and 100 days, respectively. OS and
PFS were estimated using the Kaplan-Meier product limit estimation method,
and differences in subgroups before 12 months were assessed by the log-rank
test. Cumulative incidences of relapse and NRM were analyzed together in a
competing risks framework. Competing risks analyses were also separately
applied to estimate aGVHD with the competing event death before aGVHD
and cGVHD with the competing event death before cGVHD. For neutrophil
engraftment and platelet engraftment, the competing events were graft loss,
relapse, and death before any of these events.
Subgroup differences were assessed using Gray's test. All estimates were
reported with (95% CI) confidence intervals. All P values were 2-sided, and
P < .05 was considered significant. Statistical analyses were performed using
SPSS version 22 (SPSS Inc., Chicago, IL) and R version 3.0.3 (R core team,
Vienna, Austria) using packages “prodlim” and “cmprsk.”
RESULTS
Patient Characteristics
From the EBMT registry 56 patients were identified with
primary MF or secondary MF who underwent allo-SCT from
2 antigen MMRDs. The median patient age at the time of
transplant was 57 years (range, 38 to 72). Recipients were pre-
dominantly men (57%), with 43% women. Disease type at diag-
nosis was primary MF (75%) and postpolycythemia vera/
postessential thrombocythemia MF (25%). Patient, disease,
and transplant characteristics are shown in Table 1. The
median interval from diagnosis to allo-SCT was 48 months
(range, 4 to 213). IPSS score was not complete and hence not
analyzed. Karnofsky performance status was 90 to 100 in 64%
and <90% in 36% of patients; data were missing for 6 patients.
Cytogenetic data were unfortunately largely unavailable and
hence not analyzed. Regarding mutational profile, JAK2 V617F
was mutated in 61% of patients for whom the status was
known (n = 33). Data for MPL and CALR mutations was not
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available. Because this is a registry-based study, albeit very
probable, it cannot be confirmed that all consecutive patients
from each center were submitted to the EBMT.
Donor and Transplant Characteristics
All 56 mismatched donors were relatives with 2 Ag HLA
mismatch with the recipient. Among 39 donors, for whom the
relationship was available in registry data, offspring accounted
for 87%, sibling 10%, and a donor from a further removed rela-
tive in 3%. Regarding donors, 41 (73%) were men and 15 (27%)
were women, with a median age of 32 years (range, 20 to 53).
Cytomegalovirus recipientdonor serology was / in 10%, /+
in 6%, +/ in 33%, and +/+ in 51%; data were missing in 5 cases.
As regards hematopoietic stem cell source, bone marrow was
used in 66% and peripheral blood in 34%. The median total
nucleated cell count was 7.5£ 108/kg (range, 2.4 to 17.6;
n = 11). The median CD34+ cell dose was 4.8£ 106/kg (range, 1.7
to 22.9), with available data in 43 recipients. Conditioning was
MAC in 70% of patients and reduced-intensity conditioning
(RIC) in 30%. Post-transplant cyclophosphamide (PTCy) was
used as GVHD prophylaxis in 79%, and hence 21% used alterna-
tive GVHD prophylaxis. Conditioning regimens were heteroge-
neous and are shown in Supplementary Table 1. The most
common regimen (n = 33; 59%) was thiotepa 10mg/kg, busulfan
6.4 or 9.6 mg/kg, and fludarabine 150 mg/m2 with PTCy and
cyclosporine A/mycophenolate mofetil.
Engraftment
Primary engraftment data (Table 2) were available for 56
patients. The incidence of neutrophil engraftment at 28 days was
82% (95% CI 70% to 93%), at a median time of 21 days (range, 19
to 23).
The cumulative incidence of primary graft failure at
2 years was 9% (95% CI 1% to 16%) and secondary graft failure
was 13% (95% CI 4% to 22%). Secondary graft loss occurred at a
median of 4.2 months (range, 3.5 to 12.1) after allo-SCT. The
incidence of platelet engraftment at 100 days was 70% (95% CI
53% to 88%), at a median time of 35 days (range, 27 to 81).
Three patients did not nadir platelets to below 20£ 109/L.
Subanalyses did not demonstrate any significant differences
in engraftment times for neutrophils or platelets between
peripheral blood stem cell (PBSC) and bone marrow stem cell
source, MAC versus RIC, sex mismatch or age of donor or
recipient, GHVD prophylaxis with PTCy, or CD34 dose > or
<5£ 106/kg.
Table 1
Patient Characteristics
Characteristic Value
Patient age, yr, median (range) (n = 56) 57 (38-72)
Sex (n = 56)
Male 32 (57)
Female 24 (43)
MPS subclassification (n = 56)
Primary MF 42 (75)
Secondary MF 14 (25)
Risk profile according to Lille score (n = 41)
Low 8 (20)
Intermediate 21 (51)
High 12 (29)
Splenomegaly (n = 41)
Enlarged 27 (66)
Not enlarged 14 (34)
JAK2V617Fmutation status (n = 33)
Positive 20 (61)
Negative 13 (39)
Disease status at transplant (n = 49)
No prior treatment/stable disease 33 (67)
Relapse/progression 16 (33)
Relationship HLA mismatch relative (n = 39)
Child 34 (87)
Sibling 4 (10)
Further removed 1 (3)
Donor gender (n = 56)
Female 15 (27)
Male 41 (73)
Donorrecipient (n = 56)
FM 8 (14)
FF 7 (13)
MF 17 (30)
MM 24 (43)
Stem cell source (n = 56)
Bone marrow 37 (66)
PBSCs 19 (34)
Median CD34+ infused stem cells,
£106/kg body weight (range) (n = 43)
4.8 (1.7-22.9)
Cytomegalovirus serostatus of
recipient and donor (n = 51)
Negativenegative 5 (10)
Negativepositive 3 (6)
Positivenegative 17 (33)
Positivepositive 26 (51)
Conditioning intensity (n = 56)
MAC 39 (70)
RIC 17 (30)
GVHD prophylaxis
PTCy 44 (79)
Other 12 (21)
Karnofsky performance score (n = 50)
90 32 (64)
<90 18 (36)
Values are n (%) unless otherwise defined. MPS indicates myeloproliferative
syndrome.
Table 2
Outcomes
Outcome Value
Neutrophil engraftment (ANC > .5£ 109/L)
Days to ANC engraftment, median (95% CI) 21 (19-23)
Incidence at 28 days post-HSCT, % 82 (70-93)
Platelet engraftment (platelets > 20£ 109/L)
Days to platelet engraftment, median (95% CI) 35 (27-81)
Incidence at 100 days post-HSCT, % 70 (53-88)
2-Year cumulative incidence of primary
graft failure, % (95% CI)
9 (1-16)
Secondary graft failure, % (95% CI) 13 (4-22)
Cumulative incidence of aGVHD at 100 days, % (95% CI)
Grades II-IV 28 (16-40)
Grades III-IV 9 (2-17)
Cumulative incidence of limited/extensive
cGVHD at 1 year, % (95% CI)
Death without cGVHD 45 (32-58)
cGVHD at 2 years 20 (10-31)
Death without cGVHD 48 (34-61)
25 (12-38)
OS, %
12 months (95% CI) 61 (48-74)
24 months (95% CI) 56 (41-70)
PFS, %
12 months (95% CI) 58 (45-71)
24 months (95% CI) 43 (28-58)
CIR, %
12 months (95% CI) 7 (0-14)
24 months (95% CI) 19 (7-31)
GVHD relapse-free survival, %
12 months (95% CI) 32 (19-45)
24 months (95% CI) 21 (8-35)
NRM, %
12 months (95% CI) 35 (22-48)
24 months (95% CI) 38 (24-51)
ANC indicates absolute neutrophil count; CI, confidence interval.
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Graft-versus-Host Disease
The cumulative incidence of grades II to IV aGVHD at
100 days was 28% (95% CI 16% to 40%), whereas the cumulative
incidence of grades III to IV aGVHD at 100 days in surviving
patients was 9% (95% CI 2% to 17%) (Figure 1 A ). The cumula-
tive incidence of cGVHD at 1 year was 45% (95% CI 32% to 58%);
the cumulative incidence of limited cGHVD at 1 year was 39%
(95% CI 26% to 52%), extensive 6% (95% CI 0% to 12%), and
mortality without 20% (95% CI 10% to 31%). The cumulative
incidence of limited cGVHD at 2 years was 42% (95% CI 28% to
56%) (Figure 1B), extensive 6% (95% CI 0% to 12%), andmortality
without 25% (95% CI 12% to 38%). Those who died before
engraftment (n = 2) and failed primary engraftment (n = 5)
were not assessable for aGVHD or cGHVD.
Survival and Relapse
The median follow-up was 32 months (range, 18 to 37),
and all patients had complete survival and relapse informa-
tion. A total of 33 patients were alive at last follow-up.
Disease relapse/progression caused death in 2 patients (9%).
OS at 12 months was 61% (95% CI 48% to 74%) and at
24 months was 56% (95% CI 41% to 70%). PFS at 12 months
was 58% (95% CI 45% to 71%) and at 24 months was 43% (95%
CI 28% to 58%) Figure 2. Univariate analysis for factors affect-
ing OS and PFS are shown in Table 3. No factor was statisti-
cally significant in affecting OS or PFS. The CIR at 1 year was
7% (95% CI 0% to 14%), whereas the 2-year CIR was 19%
(95% CI 7% to 31%). Of the patients who relapsed, 8 had
engrafted previously and 1 patient was reported as secondary
graft failure with disease progression. The NRM was 35% (95%
CI 22% to 48%) at 1 year and 38% (95% CI 24% to 51%) at 2 years.
The causes of NRM were infection (14 patients, 61%), GVHD
(4 patients, 17%), and organ damage or failure (3 patients,
13%). Finally, GVHD relapse-free survival at 1 year was 32%
(95% CI 19% to 45%) and at 2 years was 21% (95% CI 8% to 35%),
although we recognize the caveats of using this endpoint
from registry data.
Donor Lymphocyte Infusions and Second Stem Cell
“Infusions”
Two patients had a donor lymphocyte infusion (DLI), and
both were censored (1 was lost to follow-up at approximately
1 year and 1 at 2.5 years and so was administratively censored
at 2 years.). With regard to second stem cell “top-ups,” full
details were unavailable.
Comparison between Conditioning Regimens
No significant differences in OS, PFS, CIR, NRM, or aGVHD
and cGVHD rates between thiotepa/busulfan/fludarabi-
nePTCy and other MMRD conditioning regimens were evi-
dent, although it must be acknowledged that this is a small
cohort. No difference in OS, PFS, or GVHD-free relapse-free sur-
vival was evident between patients transplanted with PTCY as
GVHD prophylaxis (n = 44) versus those who had other GVHD
prophylaxis (n = 12).
DISCUSSION
It is well established that allo-SCT for MF can be curative and
is normally reserved for those with IPSS/DIPSS intermediate-II or
high-risk disease who have a suitable donor and no contraindica-
tion to allo-SCT [3,9]. Although MSDs appear to consistently pro-
vide better outcomes, MUDs have been reported to result in
inferior outcomes in some reports [914] but equivalent in
others [3]. Current donor algorithms, although under review,
would place an MMRD as an alternative to cord blood transplan-
tation for MF cases lacking an MSD or MUD/MMUD. Collectively,
however, outcomes from MMUDs in MF tend to suggest adverse
outcomes as regards both relapse-free and OS with NRM
approaching 38% at 1 year in some published cohorts; hence, it is
important to understand the role of MMRDs [3,4]. In this retro-
spective registry analysis we demonstrate, in the largest cohort
published to date, that patients withMF undergoing a familymis-
matched/haploidentical allo-SCT can achieve engraftment with
acceptable levels of both aGVHD or cGVHD and encouraging PFS
and OS rates.
In the current series failure of sustained engraftment
occurred in up to 22% of patients. Although these rates of graft
failure appear to be comparable with previous reports from
unrelated donors [911], they contrast with the 95% engraft-
ment rate reported by Bregante et al. [7] for MMRDs using a
myeloablative, dual alkylator thiotepa, busulfan, and PTCy con-
ditioning with bone marrow as the stem cell source. Factors
that may have affected engraftment in that series were antici-
pated and preemptive interventions planned such as splenec-
tomy if splenic dimensions were 22 cm (in 24% of recipients),
aiming for a higher CD34 cell dose of >3.3£ 106/kg recipient
body weight and managing primary engraftment with a CD34+
selected PBSC infusion if chimerism was >99% but in the pres-
ence of poor counts. If chimerism was less than 100% a fludara-
bine/Cy/TBI PBSC haploidentical allo-SCT was performed. Each
of these strategies would be of potential value to enhance
engraftment with MMRDs, and these data suggest that their
timely deployment yields good results. It must also be noted
Figure 1. (A) Cumulative incidence of aGVHD grades III to IV. (B) Cumulative incidence of cGVHD until 2 years after transplant.
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that with registry data we are relying on adequate definition of
secondary graft failure by the treating physicians.
In our retrospective multicenter series only 2 patients
received DLIs, the median CD34 cell dose was higher but with a
wider range, and data on second grafts or stem cell boosts were
not readily available. Bone marrow was the stem cell source in
61% of the patients in this cohort but appeared not to affect
engraftment rates or the conditioning regimen intensity. Strate-
gies in place for sibling and MUD transplants probably need to
be used to enhance and maintain engraftment including consid-
eration of DLIs and an early second SCT in the event of poor graft
function or late graft failure. Moreover, in the setting of bulky
splenomegaly and primary graft failure, consideration could be
given to post-SCT splenectomy. Given the rates of graft failure,
it may be warranted to have potential second donors identified
in case these are needed on an emergent basis. Issues with sus-
tained engraftment would have also contributed to the rela-
tively high NRM in this cohort, akin to what has been described
for MMUD in MF. The authors did not have access to chimerism
data and did not attempt to differentiate between the physician
nominated relapse or graft failure, and it is possible due to the
difficulty with applying these definitions that mortality attrib-
uted to relapse may be NRM and vice versa.
In general, aGVHD rates within this cohort appeared to be
relatively low at 28% for grades II to IV (16% to 40%) and 9% for
grades III to IV (2% to 17%). However, the cumulative incidence
of limited/extensive cGVHD at 2 years was 48% (34% to 61%),
similar to that experienced with MUDs in previous studies
[912]. Regarding relapse, although a longer follow-up period
is required, the CIR was 19% at 2 years and is not dissimilar to
the long-term results from the prospective EBMT RIC-alloSCT
study, which demonstrated a relapse risk of up to 22% at 3
years and approximately 28% at 5 years [3].
NRM in this series was relatively high andmay be dependent
on the type of donor used. Prospective data from the FLudara-
bine Busulphan Anti-thymocyte Globulin (FBATG) reduced
intensity conditioned peripheral blood stem cell haploidentical
transplants [3] reported by the EBMT were 16% but varied by
donor from 10% MSD to 38% for MMUD. Likewise, NRM was
also high in the prospective study of MF patients conditioned
with fludarabine-melphalan-antithymocyte globulin [14] where
NRM was 22% in the sibling donor and up to 59% in the unre-
lated donor group. However, engraftment was lower at 79% for
unrelated donors compared with sibling donors, and this may
well directly influence the high NRM rates. The NRM with both
Volunteer unrelated donor (VUD) and haploidentical donors
where engraftment rates exceeded 95% was low at 16% [3,4].
MMUD outcomes were worse with an increased hazard
ratio for both OS and NRM compared with both MSDs and
MUDs. Of note, it was previously hypothesized that recipients
with MF may be more sensitive to HLA disparity due to the
nature of their underlying disease and general debilitation,
and indeed perhaps one could hypothesize the inherent
immune deregulation [15]. Initial reports concerning the use
of umbilical cord blood for patients with fibrotic bone marrows
reported neutrophil engraftment between 80% and 93% by day
60, early full donor chimerism by day 14, and low aGVHD of
36%. However, the OS at 4 years was disappointing at 29%,
Figure 2. (A) OS and (B) PFS post-transplant of the entire cohort as estimated by the Kaplan-Meier method. (C) CIR and NRM for the entire cohort. (D) GVHD-free
relapse-free survival.
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because of a high rate of relapse and a high transplant-related
mortality at 35% [6,16,17]. Higher relapse rates and worse sur-
vival make this a less attractive stem cell source, compounded
by the fact that strategies to enhance or maintain engraftment
are limited by the current inability to boost the graft source.
There has been a global increase in MMRD transplants [18]
with both T celldepleted [19] and unmanipulated graft proto-
cols conditioned with either antithymocyte globulin [20] or
PTCy [21,22]. However, MMRD transplants in MF have been lim-
ited to small numbers included in large series of patients trans-
planted for MF [4] or haploidentical transplant protocol
development for hematologic disease [23]. Raiola et al. [23]
described the use of thiotepa, busulfan, and fludarabine or TBI
and fludarabine with PTCy, cyclosporine, and mycophenolate
mofetil as GVHD prophylaxis and bone marrow as the graft
source for a variety of conditions. Updated results included 16
MF patients among a total of 148 patients. Impressively, only
1 patient with MF and an enlarged spleen failed to engraft
[23,24]. In both these studies the median time to neutrophil
engraftment was 18 days. aGVHD grades II to IV was 24% with
10% experiencing grades III to IV aGVHD, and the cumulative
incidence of moderate to severe cGVHD was 12%. This study
suggested that patients older than 60 experienced higher
aGVHD and cGVHD rates and that disease phase predicted
relapse [24].
A major drawback of our current study is the absence of
both molecular and cytogenetic data in describing overall
patient risk, and that may aid prediction of outcomes after
allo-SCT. Molecular monitoring should be investigated pro-
spectively in this setting. Furthermore, there are little data to
guide the use of DLI, either preemptive or salvage, in the set-
ting of MMRD for MF. Others [2527] have previously
described the effective use of CD34+ selected stem cell infusion
for poor graft function and DLI for mixed-donor chimerism in
MSD and MMUD transplants. Prospective studies of these
approaches in the MMRD setting are needed to see if rates of
late graft loss, as highlighted by our study, can be reduced. It
will also be important to study the effect of HLA donor-
directed antibodies in mediating graft rejection in this setting.
In conclusion, we demonstrate in a large cohort of MF
patients the feasibility of using an MMRD approach with over
80% neutrophil engraftment, acceptable GVHD, and OS at a
median of 2.5 years follow-up. Strategies to enable sustained
engraftment and reduce relapse and NRM that remain relatively
Table 3
Univariate Analysis of Factors Affecting OS and PFS Outcomes at 1 Year after Allo-SCT Are Reported for Subgroups
No. of Cases 1 -Year OS
(%)
1 -Year PFS
(%)
1 -Year GVHD-Free Relapse-Free Survival
(%)
Total 56 61 (48-74) 58 (45-71) 32 (19-45)
Age
<60 yr 33 63 (46-80) 56 (39-74) 37 (19-55)
60 yr 23 60 (39-80) 60 (39-80) 26 (8-44)
P = .9 P = .5 P = .4
Gender
Male 32 56 (39-73) 50 (32-67) 25 (10-41)
Female 24 69 (51-88) 69 (51-88) 45 (24-66)
P = .3 P = .1 P = .2
Donorrecipient gender match
FM 8 50 (15-85) 38 (4-71) 14 (0-40)
FF 7 71 (38-100) 71 (38-100) 50 (10-90)
MF 17 69 (46-92) 69 (46-92) 43 (18-68)
MM 24 58 (38-78) 54 (34-74) 29 (10-47)
P = .8 P = .4 P = .4
JAK2
Wild-type 13 85 (65-100) 77 (54-100) 31 (6-56)
Mutated 20 50 (28-72) 50 (28-72) 30 (10-50)
P = .07 P = .2 P = .5
Interval of diagnosis to transplant
<36 mo 23 78 (60-95) 73 (54-92) 40 (20-61)
36 mo 33 52 (34-69) 48 (31-66) 29 (13-45)
P = .09 P = .1 P = .4
Diagnosis
Primary MF 42 63 (49-78) 61 (46-76) 31 (17-45)
Secondary MF 14 55 (28-82) 48 (21-75) 42 (14-70)
P = .8 P = .4
TBI
No 50 62 (48-75) 60 (46-73) 35 (22-49)
Yes 6 62 (21-100) — —
P = .9
Stem cell source
Bone marrow 37 61 (46-77) 61 (46-77) 30 (15-45)
PBSCs 19 61 (39-84) 51 (27-74) 40 (17-64)
P = 1 P = .4 P = .7
PTCy
No 12 73 (47-99) 65 (37-93) 42 (14-70)
Yes 44 58 (43-73) 56 (41-71) 31 (17-45)
P = .2 P = .4 P = .6
MAC
No 17 55 (29-80) 48 (22-74) 34 (9-60)
Yes 39 64 (49-79) 62 (46-77) 34 (18-48)
P = .5 P = .3 P = .9
Values in parentheses are 95 confidence intervals.
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high need to be used in prospective studies to improve out-
comes. Further comparisons of MUD and MMUD transplants are
required with longer follow-up in a prospective fashion.
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